PRAME expression is also considered an indicator of poor prognosis in several tumor types, including breast cancer, uveal melanoma, hepatocellular carcinoma, Hodgkin’s lymphoma, and neuroblastoma [6–10]. This evidence concerns the gene PRAME and hepatocellular carcinoma.